Literature DB >> 22964467

Prostaglandin E2 receptor subtypes in human blood and vascular cells.

Nabil Foudi1, Ingrid Gomez, Chabha Benyahia, Dan Longrois, Xavier Norel.   

Abstract

Prostaglandin E(2) is produced in inflammatory responses via the cyclooxygenase pathway and regulates a variety of physiological and pathological reactions through four different receptor subtypes; EP(1), EP(2), EP(3) and EP(4). The role of the classical prostanoid receptors stimulated by prostaglandin I(2) and thromboxane A(2) in the blood circulation has been largely studied, whereas the other receptors such as EP activated by prostaglandin E(2), have been recently shown to be also implicated. There is now increasing evidence suggesting an important role of EP(3) and EP(4) receptor subtypes in the control of the human vascular tone and remodeling of the vascular wall as well in platelet aggregation and thrombosis. These receptors are implicated in vascular homeostasis and in the development of some pathological situations, such as atherosclerosis, aneurysms and hypertension. The use of specific EP agonists/antagonists would provide a novel cardiovascular therapeutic approach. In this review, we discuss the role of prostaglandin E(2) receptors in the control of human blood and vascular cells.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22964467     DOI: 10.1016/j.ejphar.2012.08.009

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Prostaglandin E2 signals white-to-brown adipogenic differentiation.

Authors:  Verónica García-Alonso; Joan Clària
Journal:  Adipocyte       Date:  2014-12-10       Impact factor: 4.534

2.  α1 -Adrenoceptor activation of PKC-ε causes heterologous desensitization of thromboxane receptors in the aorta of spontaneously hypertensive rats.

Authors:  Yingzi Zhao; Paul M Vanhoutte; Susan W S Leung
Journal:  Br J Pharmacol       Date:  2015-05-15       Impact factor: 8.739

3.  Role of COX-2-derived PGE2 on vascular stiffness and function in hypertension.

Authors:  M S Avendaño; S Martínez-Revelles; A Aguado; M R Simões; M González-Amor; R Palacios; P Guillem-Llobat; D V Vassallo; L Vila; J García-Puig; L M Beltrán; M J Alonso; M V Cachofeiro; M Salaices; A M Briones
Journal:  Br J Pharmacol       Date:  2016-03-21       Impact factor: 8.739

4.  Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.

Authors:  Corey Cutler; Pratik Multani; David Robbins; Haesook T Kim; Thuy Le; Jonathan Hoggatt; Louis M Pelus; Caroline Desponts; Yi-Bin Chen; Betsy Rezner; Philippe Armand; John Koreth; Brett Glotzbecker; Vincent T Ho; Edwin Alyea; Marlisa Isom; Grace Kao; Myriam Armant; Leslie Silberstein; Peirong Hu; Robert J Soiffer; David T Scadden; Jerome Ritz; Wolfram Goessling; Trista E North; John Mendlein; Karen Ballen; Leonard I Zon; Joseph H Antin; Daniel D Shoemaker
Journal:  Blood       Date:  2013-08-30       Impact factor: 22.113

5.  Decreased PGE₂ content reduces MMP-1 activity and consequently increases collagen density in human varicose vein.

Authors:  Ingrid Gomez; Chabha Benyahia; Liliane Louedec; Guy Leséche; Marie-Paule Jacob; Dan Longrois; Xavier Norel
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

6.  Prostaglandin E2 prevents hyperosmolar-induced human mast cell activation through prostanoid receptors EP2 and EP4.

Authors:  Ivonne Torres-Atencio; Erola Ainsua-Enrich; Fernando de Mora; César Picado; Margarita Martín
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

Review 7.  Inflammatory Mediators in Atherosclerotic Vascular Remodeling.

Authors:  Bryce R Evans; Anaïs Yerly; Emiel P C van der Vorst; Iris Baumgartner; Sarah Maike Bernhard; Marc Schindewolf; Yvonne Döring
Journal:  Front Cardiovasc Med       Date:  2022-05-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.